ACTRN12621001545853尚未招募1 期
A Phase 1c, Single Centre Study Investigating the Safety and Tolerability of a Lysyl Oxidase Inhibitor (PXS-6302) vs Placebo in the Amelioration of Established Scars.
niversity of Western Australia0 个研究点目标入组 50 人开始时间: 2021年11月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •To be eligible for study entry subjects must satisfy all of the following criteria:
- •1.Male or female and aged between 18 and 60 years (inclusive) at the screening visit;
- •2.Body Mass Index (BMI) between 18.0 kg/m2 and 32.0 kg/m2 (inclusive) at the screening visit;
- •3.Have a scar duration between 1-5 years.
- •4.Adequate venous access in the left or right arm to allow collection of a number of blood samples;
- •5.A male subject is eligible to participate if he agrees to using one medically approved (i.e., mechanical or pharmacological) contraceptive measure and have their partners agree to an additional barrier method of contraception for the duration of the study and for 90 days after the last administration of study drug; Women of childbearing potential must use effective contraception. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence
- •6.Able to understand, give consent, and comply with all scheduled study visits, procedures and restrictions.
排除标准
- •Subjects will be excluded from the study if one or more of the following criterion are applicable:
- •1.Clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, skin, or cardiovascular disease or any other condition, that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results;
- •2.Current acute skin condition (eg: eczema, psoriasis, broken skin, wounds etc) or large tattoos or excess hair at the study drug application site. Normal hair coverage and small blemishes are acceptable at the discretion of the Investigator.
- •3.History of keloid scarring.
- •4.History of immediate hypersensitivity to any medication or currently suffers from clinically significant systemic allergic disease;
- •5.Presence of a recent musculoskeletal injury or currently healing fracture;
- •6.Have received or is anticipated to receive any prescription systemic or topical medication within 14 days prior to the start of dosing or within 5 half-lives of the study drug, whichever is greater, or use of any over-the-counter, complementary or alternative medicine 48 hours prior to the start of dosing (with the exception of paracetamol up to 2g per day, the use of intra-nasal and inhaled corticosteroids or antihistamines and vitamins);
- •7.At Investigator discretion if systolic blood pressure <90 or >140 mmHg, diastolic blood pressure <50 or >95 mmHg, and heart rate <40 or >100 bpm;
- •8.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin
- •>1.5 × upper limit of normal. Test may be repeated once at the discretion of the Investigator;
- •9.Hemoglobin, white blood cell (WBC), neutrophils, platelets < lower limit of normal. Test may be repeated once at the discretion of the Investigator;
- •10.Evidence of significant renal insufficiency, as indicated by an estimated creatinine clearance using the Cockcroft-Gault formula < 80 mL/min at Screening;
- •11.Receipt of blood, or loss or donation of 450 mL or more of blood within 90 days or plasma donation within 14 days before the first dose administration;
- •12.Have received an experimental therapy within 30 days or 5 half-lives of the study drug, whichever is longer, prior to dosing;
- •13.Systemic infection other than common cold in the week prior to dosing.
- •14. Pregnant females.
研究者
相似试验
进行中（未招募）
1 期
A Study of LY3526318 in Healthy Male Japanese ParticipantsHealthyJPRN-jRCT2071220072Wakayama Naohiko34
已完成
2 期
A Phase 2a, Single-Center Study Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal FunctioNL-OMON34527Covance36
进行中（未招募）
不适用
A Phase IIa, Single-Center Study, Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/Pharmacodynamics of Oral Tolvaptan (OPC-41061) in Subjects with Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal FunctioAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 12.1Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantEUCTR2010-019025-33-NLOtsuka Pharmaceutical Development Commercialization, Inc.36
招募中
不适用
A Phase 0, single-center study to characterize the response of a UV-B skin challenge on the skin of healthy volunteers and cutaneous lupus erythematosus (CLE) patients.cutaneous lupus erythematosuslupus affecting the skin10014982NL-OMON56266Centre for Human Drug Research16
已完成
1 期
A phase I, single-centre, open study to assess the pharmacokinetic profile and safety of a 100 mg Clindamycin Hydrochloride Vaginal Insert (CHVI) in healthy femalesAcute vaginitisBacterial vaginosisUrological and Genital DiseasesISRCTN15152571Controlled Therapeutics (Scotland) Ltd (UK)10